Third Covid-19 vaccine ‘is 94.5% effective’, researchers say
The UK has not placed orders for the US-led Moderna jab, but the findings bode well for the development of other coronavirus vaccines, scientists say.
Interim data from the US firm Moderna suggests its vaccine is highly effective in preventing people getting ill and also works across all age groups, including the elderly.
The UK has not yet placed an order for the vaccine – which works in a similar way to Pfizer’s – but a Whitehall source told the PA news agency the Government was “in advanced discussions” to procure it.
Scientists said the news bodes well for other COVID-19 vaccines, with the one for Oxford University and UK pharmaceutical giant AstraZeneca due to report in the coming days or weeks.
Read more about COVID-19:
- Everything you need to know about COVID-19 immunity
- Argument for New Zealand-style Zero-COVID strategy strong, experts say
Moderna intends to submit an application for an Emergency Use Authorisation with the US Food and Drug Administration shortly and will submit further data on the vaccine’s effectiveness and safety.
The firm’s final-stage clinical trial is ongoing and includes more than 30,000 people in the US.
The interim analysis included 95 participants with confirmed cases of COVID-19, of which 90 had received the placebo and five the active vaccine.
The 95 cases included 15 older adults – aged 65 and over. This included 20 people who were not white – including 12 of whom were from Hispanic or Latino/a backgrounds, four African Americans, three Asian Americans and one who was multiracial.
Severe cases of coronavirus were also examined, including 11 severe cases in the first interim analysis.
All 11 cases occurred in the placebo group and none in the group which had received the vaccine, known currently as mRNA-1273.
Moderna said its available safety data does not indicate any significant safety concerns.
The vaccine was generally safe and well tolerated, and the majority of adverse events were mild or moderate in severity, it said.
Severe events after the first dose included injection site pain and after the second dose included fatigue, myalgia (muscle pain), arthralgia (joint pain), headache, pain, and redness at the injection site.
But these effects of the injection were generally short-lived, Moderna said.
The 94.5 per cent efficacy from this analysis could drop as further results from the clinical trial are announced.
Dr Stephen Hoge, president of Moderna, said he “grinned ear to ear” when learning about the efficacy of the vaccine.
He told BBC News: “When we got the news from the data and safety monitoring board, I’ll admit I broke character and grinned ear to ear for a minute.
“Because I didn’t expect, I don’t think any of us really hoped that the vaccine would be 94 per cent effective at preventing COVID-19 disease, that was really a stunning realisation.”
He said combined with data suggesting it can stop severe COVID-19, it means “that the vaccine really is a terrific tool for stopping the pandemic and hopefully stopping the worst of the disease that people are facing.
“When you combine it with the news of last week of Pfizer’s vaccine, you’ve got now two vaccines that are over 90 per cent effective.
“It really means I think we have the tools necessary to finally beat this virus back and I think that’s probably the best news of the day for all of us, is that there really are now solutions in our hands and we need to deliver them to the people who can use them.”
Read more about coronavirus:
- Two-thirds have long COVID symptoms 7 weeks after hospital discharge
- How do scientists develop vaccines for new viruses?
At the end of October, Moderna announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) had started the rolling review process of its vaccine.
This means the MHRA will review data as it becomes available from ongoing studies, with the ability to at some point say whether the vaccine should be licensed in the UK.
The announcement comes one week after Pfizer/BioNTech released interim study data suggesting their vaccine is more than 90 pre cent effective.
“This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months,” said Peter Openshaw, professor of experimental medicine at Imperial College London.
“First we heard 90 per cent efficacy from Pfizer and BioNTech, then the Russians said 92 per cent and now Moderna says 94.5 per cent.
“This latest press release is based on a study of 30,000 US adults, including many high-risk or elderly persons.
“This gives us confidence that the results are relevant in the people who are most at risk of COVID-19 and in most need of the vaccines.
“Moderna have also announced that the vaccine can be kept in a conventional freezer (-20°C) for up to six months, and that once thawed the vaccine can be kept for up to 30 days at standard refrigerator (2 to 8°C). This makes the vaccine much easier to deliver.”
Reader Q&A: Could we eradicate the common cold if everyone self-isolated?
Asked by: Adam King, Huddersfield
The common cold is a global disease which can be caused by more than 200 different strains of virus. Most people are infectious for a day or two before symptoms appear, and remain infectious for one or two weeks.
So to stamp out the cold, we’d need to self-isolate for at least a week after showing any symptoms, and there would need to be a ‘test and trace’ system to identify anyone who we may have been in contact with before symptoms appeared. The economic, mental health and physical health costs of so many people self-isolating would vastly outweigh the benefit of eradicating the cold.
Jason is the commissioning editor for BBC Science Focus. He holds an MSc in physics and was named Section Editor of the Year by the British Society of Magazine Editors in 2019. He has been reporting on science and technology for more than a decade. During this time, he's walked the tunnels of the Large Hadron Collider, watched Stephen Hawking deliver his Reith Lecture on Black Holes and reported on everything from simulation universes to dancing cockatoos. He looks after the magazine’s and website’s news sections and makes regular appearances on the Science Focus Podcast.